Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc

30 settembre 2026 aggiornato da: Edwin Posadas, MD

Phase II Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc

This is an open-label, multi-site study of AR Blockade with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving AR Blockade and AR Blockade + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to AR blockade that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

116

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • California
      • Duarte, California, Stati Uniti, 91010
        • Reclutamento
        • City of Hope
        • Contatto:
          • Tanya Dorff, MD
          • Numero di telefono: 626-256-4673
          • Email: tdorff@coh.org
      • Los Angeles, California, Stati Uniti, 90048
        • Reclutamento
        • Cedars-Sinai Medical Center
        • Sub-investigatore:
          • David Hoffman, MD
        • Sub-investigatore:
          • Robert Figlin, MD FACP
        • Sub-investigatore:
          • Kevin Scher, MD MBA
        • Sub-investigatore:
          • Leland Green, MD
        • Sub-investigatore:
          • Kristopher Wentzel, MD
        • Sub-investigatore:
          • Jun Gong, MD
        • Contatto:
        • Contatto:
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84112
        • Reclutamento
        • Huntsman Cancer Institute and Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

Inclusion Criteria:

  • History of castration-resistant prostate cancer with rising PSA on a contemporary ARSI (e.g. abiraterone or, enzalutamide, darolutamide). Bicalutamide, nilutamide, and flutamide will not be considered as contemporary ARSIs.

    • PSA rise will be defined as an increase in PSA of 0.2 ng/mL or higher on at least 2 separate occasions greater than 1 week apart while on an ARSI
    • Patient must be surgically castrated or have serum testosterone concentrations much be consistent with castrate levels of testosterone (under 50 ng/dL) while on LHRH analog therapy
    • Patient must have had 1 and can have up to 2 prior AR targeted agents (if patients have had previous enzalutamide, they will be considered only for arm C). therapy with the exception of apalutamide.
    • Patients may not have had previous chemotherapy with the exception of docetaxel administered for castration-sensitive disease.
  • Patients must decline or be ineligible for taxane therapy in the opinion of the treating physician.

  • Have Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1

  • Resolution of adverse events results as described below:

    • If the subject's patient's most recent line of therapy is treatment with abiraterone or enzalutamide, then all adverse events must be resolved to Grade 2 or less
    • If the subject's patient's most recent line of therapy is any other treatment for mCRPC then all Adverse events must be resolved to grade 1 or less, with the exception of fatigue, alopecia and neuropathy (which must resolve to CTCAE grade 2)
  • Adequate organ function

  • All patients must agree to use an adequate method of contraception, in the opinion of the treating investigator, while on protocol treatment and for 3 months after the last dose of protocol treatment (apalutamide/enzalutamide and/or carotuximab)

  • Written informed consent obtained from subject and ability for subject to comply with the requirements of the study

Exclusion Criteria:

  • Non-PSA producing prostate cancers such as small cell prostate cancers or those prostate cancers which exhibit radiographic progression without PSA rise
  • Other prior malignancy requiring active anticancer therapy
  • Prior exposure to carotuximab or any CD105 targeted antibody
  • Any major surgical procedure, in the opinion of the treating physician, within 2 weeks of starting therapy
  • Uncontrolled chronic hypertension defined as sustained systolic pressure (SBP) >150 mmHg or diastolic pressure (DBP) >90 despite optimal therapy
  • Active bleeding or pathologic medical conditions, including but not limited to factor deficiencies, hemophilia, etc., that carries a high bleeding risk
  • Use of thrombolytics within 10 days prior to the first day of carotuximab
  • Known hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies
  • A known diagnosis of Osler-Weber-Rendu syndrome
  • Ascites or pericardial or pleural effusion requiring external drainage procedures
  • History of untreated brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 28 days. Imaging for CNS disease will not be required for screening unless there is a history of a neurological finding such as new onset of weakness or numbness that cannot be explained by other medical history.
  • Acute cardiovascular event within the past 6 months. An acute cardiovascular event will be defined as a myocardial infarction, NYHA Class II or worse congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or CABG.
  • Deep venous thrombosis within the past 6 months, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred but clearance should be given by the local PI.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Enzalutamide Naive - Monotherapy

After progression, subjects will crossover to combination therapy

Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle

Altri nomi:
  • Enzalutamide
  • Apalutamide
Sperimentale: Enzalutamide Naive - Combination therapy (Androgen Receptor Blockade + Carotuximab)

Androgen Receptor is Apalutamide 240mg for Lead-In group & Enzalutamide 160mg for all other groups

Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle

Altri nomi:
  • Enzalutamide
  • Apalutamide

Carotuximab administered intravenously at the following doses:

Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose.

Sperimentale: Enzalutamide Exposed - Combination therapy (Androgen Receptor Blockade + Carotuximab)

Androgen Receptor is Apalutamide 240mg for Lead-In group & Enzalutamide 160mg for all other groups

Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle

Altri nomi:
  • Enzalutamide
  • Apalutamide

Carotuximab administered intravenously at the following doses:

Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression free survival (rPFS) between patients receiving AR blockade and AR blockade + carotuximab
Lasso di tempo: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

From the start of study treatment until documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3, or death due to any cause.

From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of Adverse events (grade 3 or higher) related to carotuximab and AR blockade
Lasso di tempo: From start of study treatment through 4 weeks on treatment

Grade 3 or above treatment related adverse events as assessed per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

From start of study treatment through 4 weeks on treatment
Overall radiographic response rate (ORR) of the combination of AR blockade + carotuximab
Lasso di tempo: From the start of combination study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

Participants of the combination of AR blockade + carotuximab, with confirmed complete response (CR) or partial response (PR) per RECIST v.1.1 and Prostate Cancer Working Group 3

From the start of combination study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
Proportion of patients resistant to AR blockade benefit from the addition of carotuximab
Lasso di tempo: From the start of combination therapy study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

Participants of the monotherapy group that crossover to combination therapy at progression, with confirmed complete response (CR) or partial response (PR) per RECIST v.1.1 and Prostate Cancer Working Group 3

From the start of combination therapy study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
Overall radiographic response rate (ORR) in the overall population
Lasso di tempo: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

Determined by confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3

From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
To determine the radiographic progression free survival (rPFS) in the overall population
Lasso di tempo: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

From the start of study treatment until documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3, or death due to any cause.

From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
To determine the biochemical PFS (by PCWG3) in the overall population
Lasso di tempo: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

From the start of study treatment until documented progression, per Prostate Cancer Working Group 3, or death due to any cause.

From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Investigatore principale: Edwin Posadas, MD FACP, Cedars-Sinai Medical Center

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

27 dicembre 2023

Completamento primario (Stimato)

1 gennaio 2028

Completamento dello studio (Stimato)

1 gennaio 2028

Date di iscrizione allo studio

Primo inviato

6 settembre 2022

Primo inviato che soddisfa i criteri di controllo qualità

6 settembre 2022

Primo Inserito (Effettivo)

9 settembre 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi